

# SCH 563705

Catalog No: tcsc0833



## Available Sizes

**Size:** 2mg

**Size:** 5mg

**Size:** 10mg



## Specifications

**CAS No:**

473728-58-4

**Formula:**

$C_{23}H_{27}N_3O_5$

**Pathway:**

GPCR/G Protein;Immunology/Inflammation

**Target:**

CXCR;CXCR

**Purity / Grade:**

>98%

**Solubility:**

DMSO :  $\geq 30$  mg/mL (70.51 mM)

**Observed Molecular Weight:**

425.48

## Product Description


SCH 563705 is a potent and orally available **CXCR2** and **CXCR1** antagonist, with **IC<sub>50</sub>**s of 1.3 nM, 7.3 nM and **K<sub>i</sub>**s of 1 and 3 nM, respectively.

IC<sub>50</sub> & Target: IC<sub>50</sub>: 1.3 nM (CXCR2), 7.3 nM (CXCR1)<sup>[1]</sup>, 5.2 nM (Mouse CXCR2)<sup>[2]</sup>

K<sub>i</sub>: 1 nM (CXCR2), 3 nM (CXCR1)<sup>[1]</sup>

**In Vitro:** SCH 563705 (Compound 16) is a potent and orally available CXCR2 and CXCR1 antagonist, with IC<sub>50</sub>s of 1.3 nM, 7.3 nM and K<sub>i</sub>s of 1 and 3 nM, respectively. SCH 563705 shows potent inhibition against both Gro-α and IL-8 induced human neutrophil migration (chemotaxis IC<sub>50</sub> = 0.5 nM, against 30 nM of Gro-α; chemotaxis IC<sub>50</sub> = 37 nM, against 3 nM of IL-8)<sup>[1]</sup>. SCH 563705 potently inhibits mouse CXCR2 (IC<sub>50</sub> = 5.2 nM)<sup>[2]</sup>.

**In Vivo:** SCH 563705 has good oral pharmacokinetic profiles in rats, mice, monkeys and dogs<sup>[1]</sup>. SCH 563705 (50 mg/kg p.o) reduces blood Ly6G<sup>+</sup> Ly6C<sup>+</sup> neutrophil frequency and unchanged levels of Ly6GLy6Chi monocytes. SCH563705 (3-30 mg/kg p.o) treatment causes a dosedependent elevation in plasma levels of CXCL1<sup>[2]</sup>.



All products are for RESEARCH USE ONLY. Not for diagnostic & therapeutic purposes!